ESR1 and metastatic neoplasm: In this study, we show that elacestrant is associated with a median TTNT exceeding 6 months in a heavily pretreated real-world population with ESR1-mutant MBC and a numerically longer TTNT of 8.8 months when used early in the metastatic disease course.